Novo Nordisk (NYSE: NVO) 30-day option implied volatility is at 32; compared to its 52-week range of 20 to 67 after Novo Nordisk's next-generation obesity pill amycretin demonstrated significant weight loss in patients after 12 weeks. Call put ratio 2.9 calls to 1 put as share price up 8.3%.